BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
8.08
-0.11 (-1.34%)
At close: Sep 9, 2025, 4:00 PM
8.05
-0.03 (-0.37%)
After-hours: Sep 9, 2025, 7:59 PM EDT
BioCryst Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Cash & Equivalents | 88.03 | 104.71 | 110.64 | 304.77 | 504.39 | 272.13 | Upgrade |
Short-Term Investments | 172.01 | 216.14 | 278.34 | 119.54 | 3.21 | 28.24 | Upgrade |
Cash & Short-Term Investments | 260.04 | 320.85 | 388.99 | 424.31 | 507.6 | 300.37 | Upgrade |
Cash Growth | -4.41% | -17.52% | -8.33% | -16.41% | 68.99% | 120.49% | Upgrade |
Receivables | 91.18 | 79.07 | 56.95 | 50.6 | 29.41 | 8.65 | Upgrade |
Inventory | 5.04 | 8.09 | 28.68 | 27.53 | 15.79 | 7.04 | Upgrade |
Prepaid Expenses | 12.54 | 13.75 | 19.54 | 12.59 | 9.99 | 5.53 | Upgrade |
Restricted Cash | 0.49 | 0.21 | 1.8 | 1.47 | 3.35 | 2.22 | Upgrade |
Other Current Assets | 29.17 | - | - | - | - | - | Upgrade |
Total Current Assets | 398.46 | 421.97 | 495.97 | 516.5 | 566.14 | 323.8 | Upgrade |
Property, Plant & Equipment | 20 | 19.79 | 20.91 | 15.42 | 15.19 | 10.92 | Upgrade |
Long-Term Investments | 10.1 | 20.32 | - | 18.08 | 6.83 | - | Upgrade |
Other Long-Term Assets | 28.62 | 28.34 | 0.08 | - | - | - | Upgrade |
Total Assets | 457.19 | 490.42 | 516.96 | 550 | 588.15 | 334.72 | Upgrade |
Accounts Payable | 8.59 | 11.64 | 20.89 | 14.36 | 27.81 | 18.71 | Upgrade |
Accrued Expenses | 107.11 | 113.29 | 102.88 | 87.57 | 72.67 | 55.61 | Upgrade |
Current Portion of Long-Term Debt | 35.74 | 32.68 | 23.57 | - | - | 30 | Upgrade |
Current Portion of Leases | 2.01 | 2.77 | 2.65 | 2.37 | 1.82 | 1.18 | Upgrade |
Current Unearned Revenue | - | - | - | 1.22 | 1.42 | 0.15 | Upgrade |
Total Current Liabilities | 177.16 | 160.38 | 149.99 | 105.51 | 103.72 | 105.65 | Upgrade |
Long-Term Debt | 690.64 | 795.92 | 811.27 | 733.28 | 585.46 | 244.45 | Upgrade |
Long-Term Leases | 10.53 | 10.05 | 11.24 | 5.8 | 5.96 | 3.87 | Upgrade |
Other Long-Term Liabilities | 0.45 | - | - | - | - | - | Upgrade |
Total Liabilities | 878.78 | 966.35 | 972.49 | 844.6 | 695.14 | 353.98 | Upgrade |
Common Stock | 2.1 | 2.09 | 2.06 | 1.88 | 1.84 | 1.77 | Upgrade |
Additional Paid-In Capital | 1,340 | 1,291 | 1,222 | 1,158 | 1,098 | 1,002 | Upgrade |
Retained Earnings | -1,765 | -1,770 | -1,681 | -1,455 | -1,208 | -1,023 | Upgrade |
Comprehensive Income & Other | 1.65 | 0.92 | 1.34 | 0.03 | 0.18 | 0 | Upgrade |
Shareholders' Equity | -421.59 | -475.93 | -455.53 | -294.6 | -106.99 | -19.26 | Upgrade |
Total Liabilities & Equity | 457.19 | 490.42 | 516.96 | 550 | 588.15 | 334.72 | Upgrade |
Total Debt | 738.92 | 841.42 | 848.71 | 741.45 | 593.24 | 279.5 | Upgrade |
Net Cash (Debt) | -478.88 | -520.57 | -459.73 | -317.14 | -85.64 | 20.86 | Upgrade |
Net Cash Growth | - | - | - | - | - | -59.55% | Upgrade |
Net Cash Per Share | -2.30 | -2.52 | -2.39 | -1.71 | -0.48 | 0.12 | Upgrade |
Filing Date Shares Outstanding | 209.92 | 208.96 | 206.15 | 188.45 | 184.66 | 177.18 | Upgrade |
Total Common Shares Outstanding | 209.91 | 208.54 | 205.77 | 187.91 | 184.35 | 176.88 | Upgrade |
Working Capital | 221.3 | 261.58 | 345.98 | 410.99 | 462.42 | 218.15 | Upgrade |
Book Value Per Share | -2.01 | -2.28 | -2.21 | -1.57 | -0.58 | -0.11 | Upgrade |
Tangible Book Value | -421.59 | -475.93 | -455.53 | -294.6 | -106.99 | -19.26 | Upgrade |
Tangible Book Value Per Share | -2.01 | -2.28 | -2.21 | -1.57 | -0.58 | -0.11 | Upgrade |
Machinery | - | 8.41 | 7.66 | 6.53 | 5.84 | 4.71 | Upgrade |
Construction In Progress | - | 0.1 | - | - | - | - | Upgrade |
Leasehold Improvements | - | 10.36 | 10.21 | 10.14 | 9.83 | 8.58 | Upgrade |
Updated Aug 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.